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Abstract
Background: Aggregation of the amyloid peptides, Aβ40 and Aβ42, is known to be involved in
the pathology of Alzheimer's disease (AD). Here we investigate the relationship between peptide
aggregation and cell surface binding of three forms of Aβ (Aβ40, Aβ42, and an Aβ mutant).
Results:  Using confocal microscopy and flow cytometry with fluorescently labelled Aβ, we
demonstrate a correlation between the aggregation propensity of the Alzheimer amyloid peptides
and their neuronal cell surface association. We find that the highly aggregation prone Aβ42
associates with the surface of neuronal cells within one hour, while the less aggregation prone Aβ40
associates over 24 hours. We show that a double mutation in Aβ42 that reduces its aggregation
propensity also reduces its association with the cell surface. Furthermore, we find that a cell line
that is resistant to Aβ cytotoxicity, the non-neuronal human lymphoma cell line U937, does not
bind either Aβ40 or Aβ42.
Conclusion: Taken together, our findings reveal that amyloid peptide aggregation propensity is an
essential determinant of neuronal cell surface association. We anticipate that our approach,
involving Aβ imaging in live cells, will be highly useful for evaluating the efficacy of therapeutic drugs
that prevent toxic Aβ association with neuronal cells.
Background
Alzheimer's disease (AD) is a progressive neurological dis-
order that is the most prevalent form of age-dependent
dementia [1]. The neuropathological features of AD
include amyloid deposits, neurofibrillary tangles, and
selective neuronal loss. The principle constituent of amy-
loid deposits is a peptide denoted amyloid β(Aβ), with
the most abundant forms being 40 and 42 amino acid res-
idues long and termed Aβ40 and Aβ42, respectively [2].
The endocytic pathway has been implicated in the secre-
tion and production of Aβ [3,4]. Aβ is produced from
sequential endoproteolytic cleavage of the amyloid pre-
cursor protein (APP). First, β-secretase cleavage occurs in
the acidic late endosomes [5-7] and thereafter, γ-secretase
cleavage liberates Aβ40/42 into the endosomal lumen
[8,9]. The endosomal contents can be either secreted from
the cell [10-12] or transferred to the lysosome [13]. Expo-
sure of Aβ to endosomal pH has been found to induce var-
ious changes in its conformational and oligomeric states
[14-16], with the formation of amyloid fibrils, and other
oligomeric forms [17-21].
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There is growing evidence that Aβ aggregation is the causal
event in AD pathology. Amyloid deposits of Aβ found in
the limbic and association cortices are surrounded by
signs of neurodegeneration: dead or dying neurons, acti-
vated microglial cells, and reactive astrocytes [22,23]. In
addition, Aβ-induced neurotoxicity has been demon-
strated in numerous cell culture studies [24-26]. Moreo-
ver, transgenic mice expressing AD associated mutant
human APP develop neuropathological lesions similar to
those of AD patients. Immunization of these transgenic
mice with Aβ42 aggregates reverses much of the neuropa-
thology [27,28]. A proposed hypothesis explaining this
phenomenon is that the immune system acts as a periph-
eral sink that traps Aβ and depletes it from the central
nervous system [29]. These studies provide compelling
evidence that extracellular Aβ is a significant contributor
to neurotoxicity in AD.
The cell surface represents the first site of interaction
between extracellular Aβ and neurons, and may be the
location where the neurotoxic cascade is initiated. Studies
on the neurotoxicity of Aβ indicate that aggregated Aβ is
generally more toxic than monomeric Aβ
[20,21,24,25,30]. Given that the state of aggregation
affects the neurotoxic properties of Aβ, we have sought to
determine whether the aggregation state also influences
the interaction of Aβ with the surface of neuronal cells. We
demonstrate that the surfaces of neuronal cells possess
protein-rich sites that bind Aβ, and that aggregation com-
petence is a critical requirement for cell surface binding.
Results
Aggregation propensity of Aβ is unaffected by TMR 
labelling
The studies reported here make use of tetramethylrhod-
amine (TMR) labelled Aβ (peptide sequences listed in
Table 1), where the TMR group is located on the side chain
of the N-terminal lysine. TMR was selected over other
probes because it has been shown that TMR does not
selectively partition into any particular subcellular
organelle or microenvironment [31-33] and its fluores-
cence properties are ideal for confocal microscopy [32-
34]. Furthermore, in a previous study, rhodamine (the
parent compound of TMR) has been covalently attached
to the N-terminus of Aβ40 for thermodynamic solubility
measurements, and the solubility behaviour of this
labelled peptide was similar to that of unlabelled Aβ40
[35]. We have also demonstrated that attaching a fluores-
cent label to the N-terminus of Aβ via a flexible glycine
linker does not alter its amyloidogenic properties [19,36].
We note that the N-terminus of Aβ is more accessible and
less involved in amyloidogenesis than other regions of the
sequence [37]; thus, fluorescent labelling of the N-termi-
nus is likely to have the least influence on amyloidogene-
sis.
We performed several biochemical characterizations of
the TMR-labelled peptides used in this study, and we
found that the labelled and unlabelled peptides behaved
similarly. We found that labelled versions of both Aβ40
(Figure 1A) and Aβ42 (Figure 1B) exhibited identical cir-
cular dichroism spectra to their unlabelled counterparts,
all possessing a negative band at 218 nm, which is charac-
teristic of β-structure. We also studied a double mutant
(F19S/L34P) of Aβ42 (hereon referred to as 'mutant pep-
tide'), which was discovered through a GFP-based screen
for mutations that reduce the aggregation propensity of
Aβ42. These two particular mutations were shown to
transform the highly aggregation-prone Aβ42 into a solu-
ble unstructured monomeric peptide [38]. TMR-labelled
mutant peptide was found to exhibit an unstructured con-
formation by circular dichroism (Figure 1B), even after
storage for sixty days at room temperature (pH 6). We
used thioflavin-T to assess the amyloidogenic potential of
the peptides. Thioflavin-T is a dye known to shift its fluo-
rescence from 430 nm to 490 nm upon binding specifi-
cally to the cross-β-structure of amyloids but not to the
monomeric or small oligomeric complexes [39,40]. Using
thioflavin-T fluorescence, we observed very similar pH-
dependent fluorescent emissions for both labelled and
unlabelled Aβ40 (Figure 1C) and Aβ42 (Figure 1D). Inter-
estingly, the mutant peptide did not exhibit significant
thioflavin-T fluorescence enhancement (Figure 1D). Neg-
ative stain electron microscopy revealed that TMR-
labelled Aβ40 (Figure 1E) and TMR-labelled Aβ42 (Figure
1F) could produce characteristic unbranched amyloid
fibrils. In sum, these data demonstrate that TMR-labelling
does not alter the amyloidogenic properties of these pep-
tides.
Aggregation propensity is varied amongst Aβ isoforms
The aggregation propensities of Aβ42, Aβ40, and the
mutant peptide have been recently investigated
[38,41,42]. We compared the TMR-labelled versions of
these peptides and found that they follow the same order
of aggregation propensity: Aβ42 > Aβ40 > mutant peptide.
Dynamic light scattering was used to assess the degree of
aggregation of the peptides after incubation for 90 min-
utes at room temperature, pH 6 (Figure 2A). The mutant
peptide did not oligomerize under these conditions, Aβ40
formed a bimodal distribution of small and large oligom-
ers with hydrodynamic radii of 10 and 85 nm, respec-
tively, and Aβ42 formed large oligomers with radii
centered around 55 nm but extending to particles with
radii of several hundred nm. Thioflavin-T fluorescence
was used to compare the extent of amyloidogenesis of
these peptides at pH 6 and pH 5 (Figure 2B). These pH
values (pH 6 and pH 5) were selected as they were found
to induce the largest thioflavin-T fluorescence for Aβ42
(Figure 1D) and Aβ40 (Figure 1C). Under these condi-
tions, the order of thioflavin-T fluorescence was: Aβ42 >BMC Neuroscience 2007, 8:29 http://www.biomedcentral.com/1471-2202/8/29
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Aβ40 > mutant peptide. As previously mentioned, we did
not observe significant thioflavin-T fluorescence over a
wide pH range for the mutant peptide (Figure 1D). The
mutant peptide seemed aggregation incompetent under
conditions that were conducive to forming amyloid fibres
for Aβ42 and Aβ40. Our experimental results indicate that
the rank order of aggregation propensity of the TMR-
labelled peptides is the same as their unlabelled counter-
parts.
Drastic differences in cell surface associations between Aβ 
isoforms
Using confocal microscopy to image TMR-labelled Aβ, we
examined the association of the peptides to the surface of
Table 1: Sequences of Alzheimer amyloid peptides.
Name Sequence
Aβ40 DAEFR HDSGY EVHHQ KLVFF AEDVG SNKGA IIGLM VGGVV
Aβ42 DAEFR HDSGY EVHHQ KLVFF AEDVG SNKGA IIGLM VGGVV IA
mutant Aβ42 DAEFR HDSGY EVHHQ KLVSF AEDVG SNKGA IIGPM VGGVV IA
TMR-Aβ40 (TMR)-KG DAEFR HDSGY EVHHQ KLVFF AEDVG SNKGA IIGLM VGGVV
TMR-Aβ42 (TMR)-KG DAEFR HDSGY EVHHQ KLVFF AEDVG SNKGA IIGLM VGGVV IA
TMR-mutant Aβ42 (TMR)-KG DAEFR HDSGY EVHHQ KLVSF AEDVG SNKGA IIGPM VGGVV IA
Comparable aggregation properties of TMR-labelled and unlabelled Aβ Figure 1
Comparable aggregation properties of TMR-labelled and unlabelled Aβ. (A) Similar β-sheet conformation of TMR-
labelled Aβ40 (closed circles) and unlabelled Aβ40 (open circles) was observed using circular dichroism. (B) Similar β-sheet 
conformation of TMR-labelled Aβ42 (closed squares) and unlabelled Aβ42 (open squares) was found using circular dichroism. 
Unstructured conformation of TMR-labelled mutant peptide (closed triangles) is also shown. (C) Thioflavin-T fluorescence 
indicated similar pH-dependent aggregation profiles for both TMR-labelled Aβ40 (solid line, closed circles) and unlabelled Aβ40 
(dashed line, open circles). (D) Thioflavin-T fluorescence also indicated similar aggregation profiles for both TMR-labelled Aβ42 
(solid line, closed squares) and unlabelled Aβ42 (dashed line, open squares) as well as very little aggregation produced by the 
TMR-labelled mutant peptide (dotted line, closed triangles). Electron microscopy images of TMR-labelled Aβ40 and TMR-
labelled Aβ42 amyloid fibrils are shown in (E) and (F), respectively, with 100 nm scale bars. The high similarity between labelled 
and unlabelled peptides suggests that the addition of the fluorescent label has no observable effect on the aggregation profile of 
Aβ.BMC Neuroscience 2007, 8:29 http://www.biomedcentral.com/1471-2202/8/29
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three model neuronal cell lines (PC12, N2A and SH-
SY5Y) and one non-neuronal cell line (U937). Interest-
ingly, we observed a correlation between aggregation pro-
pensity and peptide deposition on all three neuronal cell
lines (Figure 3). After incubating the cells with peptide for
12 hours, Aβ42 was observed to associate strongly with all
three differentiated neuronal cell lines in localized punc-
tate regions. Aβ40 was found to exhibit a similar punctate
association, but to a lesser extent than Aβ42. The mutant
peptide, which is aggregation incompetent, did not asso-
ciate to the surface of any of the cell lines tested. The
apparent lack of cell surface association by the mutant
peptide clearly supports the idea that cell surface associa-
tion requires a specific peptide conformation or sequence
and argues against non-specific interactions brought
about by the TMR group [32-34].
The lack of Aβ association to the human lymphoma cell
line, U937 (Figure 3) is noteworthy. Massiotti and Perl-
mutter [43] reported that U937 cells are resistant to Aβ
induced cell death. We have also found them to be resist-
ant to Aβ toxicity and incapable of binding Aβ over all
exposure times tested (data not shown). To ensure that
the lack of binding was not caused by degradation of Aβ
by U937 cells, Aβ immunoblots were performed after
exposure to U937 cells. The integrity of Aβ was main-
tained after exposure to U937 cells (see Additional file 1,
Figure S2).
Aggregation propensity of Aβ correlates with cell surface 
binding kinetics
Having established an unambiguous link between pep-
tide aggregation propensity and neuronal cell surface
association, we investigated whether there is a similar cor-
relation with cell surface binding kinetics. We treated
NGF-differentiated PC12 cells with each peptide and
monitored TMR fluorescence on live cells as a function of
time by flow cytometry analysis. Dead cells were readily
distinguished from live cells by staining with 7-AAD, a
DNA binding dye that is excluded by live cells with intact
membranes [44,45]. Figure 4 shows the striking differ-
ences in the levels of TMR florescence on live PC12 cells
within only one hour of peptide exposure. Aβ42 clearly
displayed the highest rate of cell surface association, fol-
lowed by Aβ40. In contrast, the mutant peptide showed
no apparent association with live cells.
Averaging multiple flow cytometry analyses and normal-
izing to the percentage of live cells labelled with TMR, we
were able to closely study the differences in cell associa-
tion kinetics displayed by each peptide (Figure 5). Aβ42
showed a fast binding phase (< 1 hour) in which the pep-
tide bound ~50% of the live cells present. This was fol-
lowed by a slower binding phase that occurred over a 24-
hour period. The fast binding phase was completely
Comparison of aggregation propensities of different TMR- labelled Aβ Figure 2
Comparison of aggregation propensities of different 
TMR-labelled Aβ. (A) Dynamic light scattering analysis 
indicated that very small particles (likely to be monomers) 
were present in the mutant peptide solution, two distribu-
tions of oligomers were present for Aβ40, and larger oligom-
ers were present for Aβ42. (B) Aggregation marked by 
thioflavin-T fluorescence at pH 6 and pH 5 illustrated weak 
fluorescence for the mutant peptide (Mut), moderate aggre-
gation for Aβ40, and the highest aggregation for Aβ42. The 
thioflavin-T alone sample represents the total emission peak 
area for a control sample not containing any Aβ. The data 
from these techniques indicates that the rank order of aggre-
gation propensity is Aβ42 > Aβ40 > mutant.BMC Neuroscience 2007, 8:29 http://www.biomedcentral.com/1471-2202/8/29
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absent in the binding kinetics of Aβ40. However, other
kinetic features of Aβ40 binding were found to be similar
to the slower binding phase of Aβ42. Notably, the mutant
showed no measurable interaction with live NGF differen-
tiated PC12 cells (Figure 5). The rate of Alzheimer amy-
loid peptides association with neuronal cells was directly
related to their aggregation propensity, indicating that
aggregation propensity is an essential determinant of both
the rate and amount of cell surface association.
Trypsin reduces cell surface binding of Aβ42
To determine the molecular nature of the cell surface Aβ
binding sites, we examined whether the following rea-
gents blocked Aβ binding: concanavalin A, heparinase III,
annexin V, chondroitinase ABC, cholera toxin subunit B,
and trypsin (see Materials and Methods for details). Con-
canavalin A binds mannosyl and glucosyl residues
[46,47], it can be used to block the potential binding of
Aβ to these cell surface sugars. Since heparin sulphate and
chondroitin sulfate have been suggested as possible bind-
ing sites for Aβ [48], the NGF differentiated PC12 cells
were treated with heparinase and chondroitinase (in the
presence of protease inhibitors) to remove these groups
[49]. Fluorescein-labelled annexin V was used to block
potential Aβ interactions with phospholipids. Annexin V
preferentially binds to phosphatidylserine [50], however
at high concentrations it non-specifically binds to any
negatively charged phospholipids [51]. GM1 ganglioside
has also been implicated as a potential Aβ binding mole-
cule [52]. Fluorescein-labelled cholera toxin subunit B
was used to block AβGM1 ganglioside interactions, as it is
known to bind GM1 ganglioside and is used as a marker
for lipid rafts [53-55]. All of the treatments mentioned
above failed to block binding of Aβ to the surface of live
NGF differentiated PC12 cells (Figure 6A), and co-stain-
ing of TMR and fluorescein signals was neither observed
Confocal microscopy images of various cell lines treated for 12 hours with TMR-labelled peptides Figure 3
Confocal microscopy images of various cell lines treated for 12 hours with TMR-labelled peptides. All scale bars 
are 20 μm in length. The fluorescent emissions of TMR-labelled peptides are indicated in red. Aβ42 displayed the greatest cell 
surface binding among the peptides to the differentiated neuronal cell lines (PC12, N2A and SH-SY5Y). The mutant peptide 
was not observed to associate with any of the cell lines tested. None of the peptides tested associated with the U937 cells.BMC Neuroscience 2007, 8:29 http://www.biomedcentral.com/1471-2202/8/29
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for annexin V nor cholera toxin subunit B in confocal and
flow cytometry results (data not shown). The only cellular
treatment that was observed to significantly decrease Aβ
binding was trypsin digestion (Figure 6A), indicating that
the binding sites are likely membrane proteins. We per-
formed experiments to rule out the possibility that the
reduction in Aβ42 binding is simply caused by degrada-
tion of Aβ42 by trypsin; after each trypsin treatment,
trypsin was inactivated with excess of soybean trypsin
inhibitor (SBTI) and the cells were washed thoroughly
prior to adding TMR-labelled Aβ42. In addition, Aβ
immunoblot analysis of the cell extracts and conditioned
media were performed after trypsin treatments. No prote-
olytic degradation of Aβ was detected (see Additional file
1, Figure S3). Trypsin treatment in the presence of SBTI
abrogated the effect of trypsin (Figure 6A), thus the block-
age of Aβ binding is caused by the proteolytic activity of
trypsin and not by some other process. Cellular trypsin
treatments were also observed to be concentration
dependent (Figure 6B), further supporting that trypsin
treatment abolishes the cell surface binding of the pep-
tide. Interestingly, Aβ binding was recoverable if the live
trypsin-treated cells were allowed to sit for 2 – 6 hours in
the absence of trypsin (Figure 6C). This result suggests
that after trypsin removal, continued protein synthesis
replenished the Aβ binding sites on the cell surface. Col-
Flow cytometry histogram plots showing association kinetics of TMR-labelled peptides with live NGF differentiated PC12 cells Figure 4
Flow cytometry histogram plots showing association kinetics of TMR-labelled peptides with live NGF differen-
tiated PC12 cells. The thick black line represents untreated control cell autofluorescence. Aβ42 showed rapid cell associa-
tion, whereas mutant peptide did not appear to significantly associate with the live cells. It is interesting to note the bimodal 
distribution that develops over time.BMC Neuroscience 2007, 8:29 http://www.biomedcentral.com/1471-2202/8/29
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lectively, these findings provide strong evidence that neu-
ronal cell surface proteins play a critical role in the Aβ
binding process.
TMR-labelled Aβ42 binds to unlabelled Aβ42 aggregates 
on the cell surface
Our demonstration that aggregation propensity is a pre-
requisite property for cell surface binding suggests that
cell surface proteins bind Aβ aggregates, and may serve as
seeding sites that promote further Aβ aggregation on the
cell surface. To test this possibility, we treated NGF-differ-
entiated PC12 cells with unlabelled Aβ42 (see Methods).
To visualize the unlabelled Aβ42 bound to the cell sur-
face, the cells were immunostained with a monoclonal
antibody (6E10) directed against the N-terminus of Aβ.
Control experiments, in which 6E10 and secondary anti-
bodies were applied to cells that were not treated with
Aβ42, indicated that the antibodies do not bind nonspe-
cifically to the cell surface (Figure 7B). However, immu-
nostaining of cells treated with unlabelled Aβ42 (Figure
7C) showed a punctate staining pattern that was similar to
that observed in cells treated with TMR-labelled Aβ42
(Figure 3). This similarity in staining patterns indicates
that TMR-labelling of the peptide does not perturb the cell
surface association. Sequential treatment of the cells with
unlabelled Aβ42, immunostaining with 6E10 antibody,
and TMR-labelled Aβ42 indicated co-localization of unla-
belled Aβ42 immunostaining with TMR fluorescence (Fig-
ure 7D–F). This co-localization indicates that TMR-
labelled Aβ42 binds to unlabelled Aβ42 aggregates on the
cell surface. Thus, Aβ that is bound to the cell surface is
capable of binding to other Aβ molecules from the extra-
cellular environment.
Discussion
Our investigation adapts a versatile imaging technique,
and reveals a striking correlation between the aggregation
propensity of Alzheimer amyloid peptides and their cell
surface association kinetics with neuronal cells. Previous
studies have shown that Aβ42 has a higher propensity to
aggregate [41,42,56] and is the primary constituent in
senile plaques [57,58]. However, the direct link between
neuronal cell association and peptide aggregation propen-
sity was unclear until now. Aβ40 is the primary product of
proteolytic cleavage from the amyloid precursor protein
[56]. We found that Aβ40 displays relatively slow associa-
tion kinetics with neuronal cells (Figure 5) and would be
more likely to be cleared in vivo, before initiating toxicity.
On the other hand, Aβ42 associates rapidly with neuronal
cells (Figure 5) and is thus more capable of initiating neu-
rotoxicity and plaque formation. These observations offer
insight into the early mechanism of AD onset seen with
familial mutations that lead to an increase in Aβ42 [59].
Since Aβ42 associates with cells at such a rapid rate, this
process may exceed the rate at which the aging macro-
phage machinery clears amyloid deposits, resulting in the
senile plaque core found within the brain of Alzheimer
patients. The link between aggregation propensity and cell
association becomes more evident with the double
mutant of Aβ42 [38]. This aggregation incompetent
mutant peptide does not associate with the surface of any
of the cell lines tested (Figure 3). This finding is evidence
that cell surface association of Aβrequires a specific pep-
tide sequence, conformation and/or aggregation state.
Thus, Aβ aggregation propensity plays a critical role in ini-
tiation of the amyloid cascade.
Previous studies have used dyes, radioactive Aβ, and anti-
bodies to study the interactions of Aβ with cell cultures
[60-68]. Our results (Figure 3) reveal similar punctate
staining as imaged recently with antibodies directed spe-
cifically against oligomeric structural forms of Aβ [65,66].
However, our technique allows images to be obtained
with live cells throughout the progression of Aβ aggrega-
tion, and through its multitude of intermediate states. The
major drawbacks of endpoint antibody detection with
fixed cells or limited detection of specific conformations
of Aβ are avoided by using our approach. This approach
will be especially beneficial for developing therapeutic
treatments that target specific conformations of Aβ, as the
global effect of Aβ on the cell can be monitored.
Average kinetics of TMR-labelled peptide association with  live NGF differentiated PC12 cells Figure 5
Average kinetics of TMR-labelled peptide association 
with live NGF differentiated PC12 cells. Aβ42 (solid 
line) revealed an initial rapid binding phase within the first 
hour, followed by a slower binding phase over the next 24 
hours. Aβ40 (dashed line) did not display the initial rapid 
binding phase, but was otherwise similar to Aβ42. The 
mutant peptide (dotted line) did not interact with the live 
NGF differentiated PC12 cells. This finding suggests a corre-
lation between aggregation propensity and cell association 
for Aβ.BMC Neuroscience 2007, 8:29 http://www.biomedcentral.com/1471-2202/8/29
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The novel finding that U937 human lymphoma cells are
resistant to cell surface binding by Aβ offers an excellent
control for future therapeutic testing. This cell line was
known to be resistant to Aβ toxicity [43], but the present
findings provide the first biochemical evidence that U937
cells are missing the critical cell surface constituents that
are responsible for interaction with Aβ and initiation of
Aβ deposition on the surface of neuronal cells [69]. The
lack of Aβ cell surface association was not caused by pep-
tide degradation (see Additional file 1, Figure S2) over the
course of the experiment but most likely resulted from the
absence of particular cell surface proteins. Thus, this cell
line provides a useful negative control for the identifica-
tion of these proteins.
Our studies of Aβ imaging in live cells has uncovered the
major role of membrane proteins as binding sites of
Aβ40/42 on the neuronal cell surface (Figure 6A,C). These
studies utilizing trypsin were carefully constructed to
ensure that trypsin was completely inactivated with soy-
bean trypsin inhibitor before peptide treatments were
made. Immunoblot analysis confirmed that the trypsin-
induced reduction in Aβ association was not caused by
tryptic digestion of Aβ, as lower molecular weight Aβ
derived peptides were not observed in the cell culture
media or associated with the cell pellet fraction (see Addi-
tional file 1, Figure S3).
Many cellular components have been implicated to inter-
act with Aβ [1,69,70], several of which are proteins [71-
74]. Our results that Aβ binds preferentially to neuronal
cells but not the non-neuronal cell line U937, indicates
that the membrane protein binding sites are not present
in this cell line. The membrane protein or proteins that
bind Aβ have to be identified; however, there still remains
the possibility that some of the membrane protein bind-
ing sites maybe unrelated to the amyloid cascade.
Conclusion
Our experimental system of observing interactions of flu-
orescently labelled Aβ peptides with live neuronal cells
provides a straightforward technique for evaluating
potential therapeutic compounds for their ability to block
interactions of Aβ with cell surface proteins and prevent
the neurotoxic cascade elicited by Aβ. Our study has also
revealed some of the molecular details controlling the
interactions of these peptides with neuronal cells; namely,
that aggregation propensity is a critical determinant of cell
surface binding.
Methods
All chemicals were purchased from Sigma-Aldrich (St.
Louis, MO) unless otherwise stated. The following cell
culture reagents were purchased from Gibco-Invitrogen
(Burlington, ON): D-PBS, Dulbecco's modified Eagle's
medium: nutrient mixture F-12 1:1 mixture (DMEM/
Flow cytometry fluorescence results indicating trypsin signifi- cantly reduces Aβ cell surface binding Figure 6
Flow cytometry fluorescence results indicating 
trypsin significantly reduces Aβ cell surface binding. 
(A) Cell surface treatments show that 10 μg/mL trypsin sig-
nificantly decreased Aβ42 association to NGF differentiated 
PC12 cells, while treatments that target cell surface lipids or 
carbohydrates had no effect. SBTI-inactivated trypsin had lit-
tle effect on Aβ42 association. (B) Concentration depend-
ence of trypsin treated NGF differentiated PC12 cells with 0, 
5, 10 and 100 μg/mL trypsin as indicated, followed by 1 hour 
Aβ42 treatment. (C) 10 μg/mL trypsin treatment of NGF dif-
ferentiated PC12 cells demonstrate that Aβ42 association 
with the cell surface recovers over time.BMC Neuroscience 2007, 8:29 http://www.biomedcentral.com/1471-2202/8/29
Page 9 of 13
(page number not for citation purposes)
F12), N2 supplement, nerve growth factor (NGF), penicil-
lin and streptomycin.
Peptide synthesis and purification
Aβ40 was prepared by solid-phase synthesis on a PerSep-
tive Biosystems 9050 Plus peptide synthesizer, as peptide-
amides using Val-PEG-PS resin (PerSeptiveBiosystems).
An active ester coupling procedure, employing O-(7-aza-
benzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium hex-
afluorophosphate of 9-fluorenylmethoxycarbonyl amino
acids, was used. Aβ42 and mutant Aβ42 were synthesized
similarly using Ala-PEG-PS resin (PerSeptiveBiosystems).
Before cleavage from the resin, the fluorophore, Nα-(9-
Fluorenylmethoxycarbonyl)-Nε-tetramethylrhodamine-
(5-carbonyl)-L-lysine (Molecular Probes, Eugene, OR)
(abbreviated TMR) was coupled to the N-terminus via a
glycine linker. The peptides were cleaved from the resin
with a mixture of trifluoroacetic acid, thioanisole, m-
cresol, and ethanedithiol (81:13:1:5 v/v). After incubation
for twenty minutes at 25°C, the resin was removed by fil-
tration and bromotrimethylsilane was added to a final
concentration of 12.5 % (v/v). Following incubation for
three hours, the peptides were precipitated and washed in
cold ether. The crude peptides were dissolved in 6.5 M
guanidine hydrochloride (pH 10) and purified by HPLC
using a Superdex Tricorn 10/300 GL Peptide column
(Amersham Biosciences, Piscataway, NJ) with 30 mM
NH4OH running buffer. To maintain stock peptide solu-
tions free from fibril seeds, solutions were stored at pH 10
and 4°C immediately after chromatographic separation
Cell surface aggregation of Aβ Figure 7
Cell surface aggregation of Aβ. All scale bars are 20 μm in length. (A) Schematic diagram indicating the order of cell sur-
face treatments on NGF differentiated PC12 cells, separated by wash steps indicated by the arrows. (B) Confocal microscopy 
image of cells treated with 6E10 and secondary Alexa fluor 488 labelled antibody. The absence of staining in this control indi-
cates the primary and secondary antibodies do not non-specifically bind to the cell surface. (C) Images of cells treated with 5 
μM unlabelled Aβ42 followed by immunostaining with 6E10 and secondary Alexa fluor 488 labelled antibody. (D) Images of 
cells treated with 5 μM unlabelled Aβ42 followed by immunostaining, and treatment with 1.5 μM TMR-Aβ42 using 488 nm 
laser excitation. (E) Images of cells treated with 5 μM unlabelled Aβ42 followed by immunostaining, and treatment with 1.5 μM 
TMR-Aβ42 using 543 nm laser excitation. (F) Merge confocal microscopy image indicating regions of 6E10 antibody only in 
green, TMR-labelled Aβ42 in red and co-localized regions in yellow.BMC Neuroscience 2007, 8:29 http://www.biomedcentral.com/1471-2202/8/29
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of monomeric peptides. These conditions have been pre-
viously shown to maintain the monomeric state [19].
Peptide purity and identity was confirmed using both
MALDI mass spectrometry and amino acid analysis. Con-
centrations of stock peptide solutions that were free of
fibril seeds were determined using amino acid analysis
and confirmed by either tyrosine absorbance (275 nm, ε
= 1390 cm-1 M-1) or TMR absorbance for labelled peptides
(550 nm, ε = 92000 cm-1 M-1).
Circular dichroism
Aβ was added to 2 mM borate, 2 mM citrate and 2 mM
phosphate buffer with adjusted pH. Spectra were obtained
on an Aviv model 62DS circular dichroism spectrometer
with a 0.1 cm path length quartz cuvette. Buffer spectra
were subtracted from scans of each Aβ sample spectrum
and the data were converted to mean residue ellipticity
([θ], degrees cm2 dmol-1).
Thioflavin-T assay
Peptide samples were prepared at 20 μM with 2 mM
borate, 2 mM citrate and 2 mM phosphate adjusted to par-
ticular pH values and stored in the dark at 25°C for 20
hours. Fluorescence measurements were obtained after
addition of five-fold molar excess of thioflavin-T and
incubation at room temperature for thirty minutes. The
excitation was at 440 nm and the emission peak was inte-
grated from 475 nm to 495 nm.
Election microscopy
Aβ solutions were prepared at 20 μM in 2 mM borate, 2
mM citrate and 2 mM phosphate, pH 6.5. Negatively
stained fibrils were prepared by adding peptide solutions
to charged pioloform, carbon-coated grids. After blotting
and air-drying, the samples were stained with 1% phos-
photungstic acid (pH 7). Electron microscopy images
were acquired on a Hitachi H-7000 transmission electron
microscope operated with a 75 kV accelerating voltage.
Dynamic light scattering (DLS)
Hydrodynamic radius (Rh) measurements were made at
20°C with a DynaPro DLS instrument (Protein Solutions
Inc., Piscataway, NJ). Peptides samples (pH 6) were incu-
bated at room temperature for 90 minutes. Before meas-
uring 90° light scattering intensity, samples were
centrifuged at 12000 × g for three minutes. Particle trans-
lational diffusion coefficients were calculated from decay
curves of autocorrelation of light scattering data and con-
verted to hydrodynamic radius (Rh) with the Stokes-Ein-
stein equation. Histogram of percentage mass versus Rh
was calculated using Dynamics data analysis software
(Protein Solutions Inc., Piscataway, NJ).
Cell culture
Cell lines were maintained in DMEM/F12 containing
10% fetal bovine serum (HyClone, Logan, UT) with 100
units/mL penicillin and 100 μg/mL of streptomycin. To
induce differentiation of PC12 cells, they were plated at
2.2 × 104  cells/cm2  in Lab-tech chambered coverglass
chambers and suspended in phenol red free DMEM/F12
containing N2 supplement and 10 ng/mL NGF. Cells were
differentiated for 72 hours before media was replaced and
peptide treatments were preformed. To induce differenti-
ation of N2A cells, they were plated at 1.6 × 104 cells/cm2
in Lab-tech chambered coverglass chambers and sus-
pended in phenol red free DMEM/F12. Media was
exchanged every 48 hours for six days before peptide treat-
ments were performed. To induce differentiation of SH-
SY5Y cells, they were plated at 1.6 × 104 cells/cm2 in Lab-
tech chambered coverglass chambers and suspended in
phenol red free DMEM/F12 containing N2 supplement
and 60 ng/mL NGF. Media was exchanged every 48 hours
for six days before peptide treatments were performed.
U937 cells were plated at 5.4 × 104 cells/cm2 in phenol red
free DMEM/F12 containing N2 supplement, 12 hours
before peptide treatments were performed. All cells were
maintained at 37°C in a humidified incubator with 5%
carbon dioxide.
Confocal microscopy
Fluorescent images were taken with a confocal laser-scan-
ning system consisting of an LSM 510 Zeiss confocal
microscope with a 40 × water immersion objective (n.a.
1.2) and HeNe laser with a 543 nm laser line. The temper-
ature was regulated at 37°C using a heated stage and
objective heater. The displayed images represent a single
cross-section through the center of the cells. Cell viability
and membrane integrity were confirmed with 20 μL/mL
trypan blue exclusion.
Flow cytometry
NGF differentiated PC12 cells treated with Aβ (1.5 μM)
were washed once with cold D-PBS, followed by mechan-
ical detachment with D-PBS. Collected cells were centri-
fuged (200 × g for 1 minute) and resuspended in cold flow
buffer containing 5 mM EDTA and 1% BSA (Fisher Scien-
tific, Nepean, ON) in D-PBS. Samples were immediately
analyzed with a FACS Calibur flow cytometer (Becton
Dickinson, Mississauga, ON). TMR-labelled samples were
detected with 585/42 filter collecting 5 × 104 events per
sample using 100–300 events/s flow rate. Cell viability
was assessed with 25 μg/mL 7-Aminoactinomycin D (7-
AAD) treatment for 5 minutes and detected with a long
pass 650 nm filter. Data collection and analysis were per-
formed using Cell Quest version 3.3 and figures were cre-
ated using WinMDI version 2.8 software.BMC Neuroscience 2007, 8:29 http://www.biomedcentral.com/1471-2202/8/29
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Blocking the binding of Aβ to the surface of live PC12 cells
Various treatments to block or remove lipid, carbohy-
drate, or protein components from the surface of live
PC12 cells were performed and their effects on Aβ binding
was examined. NGF differentiated PC12 cells were treated
with 100 ng/mL FITC labelled annexin V (to block nega-
tively charged phospholipids) or 10 μg/mL FITC labelled
cholera toxin subunit B (to block GM1 ganglioside) for 20
minutes before addition of Aβ42 (final concentration 1.5
μM) for two hours. NGF differentiated PC12 cells were
treated with 250 μg/mL concanavalin A (to block manno-
syl and glucosyl residues) for 20 minutes before addition
of Aβ42 (final concentration 1.5 μM) for two hours. NGF
differentiated PC12 cells were treated with 500 mU hepa-
rinase III (to remove heparin sulphate) or 500 mU chon-
droitinase ABC (to remove chondroitin sulfate) for 15
minutes in the presence of a proteinase inhibitor solution
(10 mM EDTA, 5 mM Phenylmethylsulphonylfluoride,
50 mM sodium acetate in D-PBS) at 37°C [48,49]. The
cells were then rinsed with media before treatment with
Aβ42 (final concentration 1.5 μM) for an hour. To remove
protein surface interactions, NGF differentiated PC12
cells were treated with 5 μg/mL, 10 μg/mL or 100 μg/mL
trypsin (9590 units/mg) for 15 minutes, followed by
addition of three molar equivalents of soybean trypsin
inhibitor (SBTI 10000 units/mg) for 5 minutes, then
media was exchanged and the cells treated with Aβ42
(final concentration 1.5 μM). NGF differentiated PC12
cells were also treated with a mixture of 10 μg/mL trypsin
and 30 μg/mL SBTI for 15 minutes, followed by media
exchange and one hour treatment with Aβ42 (final con-
centration 1.5 μM). After Aβ42 addition, treated cells and
untreated control cells were analyzed using flow cytome-
try.
Immunostaining Aβ on the surface of live PC12 cells
NGF differentiated PC12 cells treated with unlabelled
Aβ42 (5 μM) for two hours at 37°C were washed once
with cold blocking solution, containing 1% BSA (Fisher
Scientific, Nepean, ON) and 0.1 % sodium azide in D-
PBS, followed by 15 minute incubation at 4°C in cold
blocking solution. Unlabelled Aβ42 was detected by incu-
bation with a 12.5 μg/mL of 6E10 antibody (A1474,
Sigma, St. Louis, MO), followed by incubation with 10
μg/mL of secondary rabbit anti-mouse Alexa fluor 488
conjugated antibody (A-11059, Gibco-Invitrogen, Burl-
ington, ON) at 4°C in cold blocking solution. Following
antibody removal and washing with cold blocking solu-
tion, NGF differentiated PC12 cells were treated with
TMR-labelled Aβ42 (1.5 μM) in phenol red free DMEM/
F12 containing N2 supplement and 10 ng/mL NGF for
one hour at 4°C prior to confocal imaging.
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